DMRA

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1,

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026.

– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR

BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to two newly-hired, non-executive employees.

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24,

-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) --

-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3

-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with two clinical proof-of-concept datasets expected mid-2027 -- -- Strong financial

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, 2026, to four newly-hired, non-executive employees.

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on